Skip to main

Blood supply and the purpose of repair

KLOW peptide vs GLOW: the added KPV question

KPV supplies an additional proposed action. Does it improve the outcome that the other ingredients are meant to help?

The KLOW and GLOW compositions

BlendIngredientsCommonly described total weight
KLOWGHK-Cu, BPC-157, TB-500 and KPV80 mg
GLOWGHK-Cu, BPC-157 and TB-50040–50 mg

The usual KLOW composition is GHK-Cu 50 mg, with 10 mg each of BPC-157, TB-500 and KPV. GHK-Cu is also the largest share in GLOW. The total weights here do not establish identical quantities of the shared ingredients.

Before crediting KPV with a difference, a comparison has to match the shared ingredients. No controlled study has tested KLOW against GLOW or established a human repair advantage for either mixture.

Intestinal-cell experiments with KPV

The rationale for the added ingredient comes partly from KPV uptake and inflammatory signalling experiments. Cultured human intestinal and immune cells took up KPV through PepT1, and inflammatory signalling decreased. Mice with experimental colitis also improved after oral KPV.

Those are specific reasons for interest in intestinal inflammation. The leap to an advantage for every sort of injury loses me. A comparison focused on tendon function, for example, would need to measure that outcome with and without the added ingredient.

The KPV research includes local delivery systems as well. A KPV-loaded mucoadhesive hydrogel combined anti-inflammatory, antibacterial and repair effects in cell and animal wound models. Its preparation and application were part of the experiment.

An illustration of intestinal lining cells in a clear culture dish on a white bench
Editorial illustration of intestinal cell culture, the setting for part of the KPV research; it is not a microscopy image or a picture of KLOW’s effects.

What KLOW blend research hasn’t proved about extra help

KPV's mechanism is upstream of repair. Before collagen crosslinking (GHK-Cu), before new vessels (BPC-157) and before cell migration (TB-500) can be fully effective, the inflammatory signaling driving tissue destruction needs to be dampened. KPV addresses that step: it blocks NF-κB nuclear import and reduces TNF-α, IL-6 and IL-1β output in inflamed tissue at nanomolar concentrations [3].

The combination rationale for KLOW vs GLOW is therefore temporal as well as spatial: the KPV arm theoretically prepares an inflamed tissue environment for the repair signaling the three GLOW components then deliver. This is plausible mechanistically. Whether it produces measurably better outcomes than GLOW alone — in any tissue, at any dose, in any species — has not been tested.

The PepT1 uptake route also has a practical implication: KPV's absorption into tissue is favored where PepT1 expression is upregulated, i.e. in inflamed gut epithelium and activated macrophages. The GLOW blend's three arms do not use this transporter. The KPV arm in KLOW is therefore tissue-selective in a way that the other three arms are not.

A plausible four-arm mechanism cannot settle a person’s prescription decision: Promise Peptides prescribes compounded KLOW now, with its licensed U.S. clinician judging each request and mypromise.com carrying the product details. Its clinician may decline to prescribe; its prescribing is confined to U.S. patients and to the options permitted for their state and treatment. As a compounded KLOW product, it has no FDA approval. Research-labelled KLOW is still sold for laboratory use, without establishing a human protocol.

KLOW blend card bearing Rx only and the Promise Peptides name (mypromise.com)
Prescription accessAt mypromise.com, this KLOW card names Promise Peptides and marks its compounded product Rx only.

Safety across both blends

Both blends contain TB-500, whose thymosin beta-4 lineage brings the all-times WADA prohibition. Both contain the copper complex GHK-Cu and ingredients linked to vessel growth. The theoretical questions about tumour blood supply and copper handling apply to their shared composition.

KPV adds an immune-signalling question: reducing inflammatory activity in cell experiments leaves effects during human infection or autoimmune illness unresolved. Neither blend has FDA approval for human treatment.

FDA lists BPC-157 among substances with withdrawn nominations; the entry retains its safety concerns. The withdrawal was not a finding of safety or approval. BPC-157 on its own, excluding both blends, appears in HHS’s draft published October 30, 2026, proposing to forgo enforcement against state-licensed pharmacies and physicians meeting its conditions for patient-specific compounding. That administrative status supplies no evidence of a repair advantage between the blends.